Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Mar 15;76(11):968-75.
doi: 10.1212/WNL.0b013e3182104407.

Early recognition of poor prognosis in Guillain-Barre syndrome

Affiliations
Randomized Controlled Trial

Early recognition of poor prognosis in Guillain-Barre syndrome

C Walgaard et al. Neurology. .

Abstract

Background: Guillain-Barré syndrome (GBS) has a highly diverse clinical course and outcome, yet patients are treated with a standard therapy. Patients with poor prognosis may benefit from additional treatment, provided they can be identified early, when nerve degeneration is potentially reversible and treatment is most effective. We developed a clinical prognostic model for early prediction of outcome in GBS, applicable for clinical practice and future therapeutic trials.

Methods: Data collected prospectively from a derivation cohort of 397 patients with GBS were used to identify risk factors of being unable to walk at 4 weeks, 3 months, and 6 months. Potential predictors of poor outcome (unable to walk unaided) were considered in univariable and multivariable logistic regression models. The clinical model was based on the multivariable logistic regression coefficients of selected predictors and externally validated in an independent cohort of 158 patients with GBS.

Results: High age, preceding diarrhea, and low Medical Research Council sumscore at hospital admission and at 1 week were independently associated with being unable to walk at 4 weeks, 3 months, and 6 months (all p 0.05-0.001). The model can be used at hospital admission and at day 7 of admission, the latter having a better predictive ability for the 3 endpoints; the area under the receiver operating characteristic curve (AUC) is 0.84-0.87 and at admission the AUC is 0.73-0.77. The model proved to be valid in the validation cohort.

Conclusions: A clinical prediction model applicable early in the course of disease accurately predicts the first 6 months outcome in GBS.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Predicted fraction of patients unable to walk independently according to modified Erasmus GBS Outcome Score (mEGOS)
Predicted fraction of patients unable to walk independently at 4 weeks (black lines), 3 months (red lines), and 6 months (green lines) on the basis of the mEGOS at hospital admission (A) and at day 7 of admission (B). The gray areas around the colored lines represent 90% confidence intervals.
Figure 2
Figure 2. Comparing 3 therapeutic study populations with respect to prognostic factors at hospital admission using modified Erasmus GBS Outcome Score (mEGOS)
Points represent the percentages of patients with a specific mEGOS in a therapeutic trial comparing plasma exchange vs IV immunoglobulin (IVIg) (green), a therapeutic trial comparing IVIg/placebo vs IVIg/methylprednisolone (red), and an observational study (black). Smoothed lines represent the distribution of the study population over the total mEGOS.

References

    1. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939–950 - PubMed
    1. Roozenbeek B, Maas AI, Lingsma HF, et al. Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment? Crit Care Med 2009;37:2683–2690 - PubMed
    1. The Italian Guillain-Barré Study Group The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;119:2053–2061 - PubMed
    1. Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;60:1146–1150 - PubMed
    1. Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758–765 - PubMed

Publication types